Multiple Myeloma Clinical Trials in Irvine, California

12 studies are recruiting for multiple myeloma in Irvine, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma

    This Phase Ib, multicenter, open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of cevostamab monotherapy, cevostamab plus pomalidomide and dexamethasone (Pd) or cevostamab plus daratumumab and dexamethasone (Dd) which will be administered to pa…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    City of Hope - Lennar Foundation Cancer Center, Irvine, California
    Locations
    34 in total
    Run by
    Genentech, Inc.
  2. Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

    The purpose of this study is to assess the efficacy and safety of cevostamab in combination with pomalidomide and dexamethasone (CevosPd) versus standard of care (SOC) in participants with multiple myeloma (MM) who have received one to three prior lines of therapy and have been exposed to an anti-C…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    City of Hope - Lennar Foundation Cancer Center, Irvine, California
    Locations
    75 in total
    Run by
    Hoffmann-La Roche
  3. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

    The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexamethasone (DRd).

    Stage
    Phase 3
    Ages
    18 and older
    Site
    City of Hope Orange County Lennar Foundation Cancer Center, Irvine, California
    Locations
    270 in total
    Run by
    Janssen Research & Development, LLC
  4. A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

    The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    City of Hope Orange County Lennar Foundation Cancer Center, Irvine, California
    Locations
    144 in total
    Run by
    Janssen Research & Development, LLC
  5. A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

    The purpose of this study is to evaluate how well JNJ-79635322 works (efficacy) in participants with Relapsed or Refractory Multiple Myeloma (RRMM; a cancer that forms in a type of white blood cells called a plasma cell. Cancer is called relapsed if it comes back after treatment and is called 'refr…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    City of Hope Orange County Lennar Foundation Cancer Center, Irvine, California
    Locations
    71 in total
    Run by
    Janssen Research & Development, LLC
  6. A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

    The purpose of this study is to evaluate how well JNJ-79635322 works when compared with teclistamab.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    UC Irvine Health Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California
    Locations
    151 in total
    Run by
    Janssen Research & Development, LLC
  7. MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

    The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer). This study is seeking participants who: * Are 18 years of age or older and have MM. * Have received treatments befo…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Hoag Health Center Irvine, Irvine, California
    Locations
    270 in total
    Run by
    Pfizer
  8. AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

    This is a Phase I/II, modular, open-label, multicenter, dose escalation, and dose expansion/optimization study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics and efficacy of AZD0305 as monotherapy and in combination with other anticancer agents in participants with MM.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Research Site, Irvine, California
    Locations
    43 in total
    Run by
    AstraZeneca
  9. A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)

    Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety, tolerability, and how ABBV-438 moves through the body, in adult participants with relapsed/refractory (R/R) MM. Adverse events, to…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    City of Hope - Orange County Lennar Foundation Cancer Center /ID# 279067, Irvine, California
    Locations
    11 in total
    Run by
    AbbVie
  10. A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations

    Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapse…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    City of Hope - Orange County Lennar Foundation Cancer Center /ID# 277911, Irvine, California
    Locations
    34 in total
    Run by
    AbbVie
  11. Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

    This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.

    Stage
    Phase 4
    Ages
    18 and older
    Site
    UCI Health - Irvine Infusion Pharmacy ACC, Irvine, California
    Locations
    33 in total
    Run by
    Pfizer
  12. A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma Patients

    This study assesses the impact of cannabis (also commonly called marijuana, weed, or THC) use on quality of life among patients with multiple myeloma who are receiving chemotherapy. It also evaluates the potential benefits and harms of cannabis use.

    Stage
    Not phased
    Ages
    18 and older
    Site
    City of Hope at Irvine Lennar, Irvine, California
    Locations
    11 in total
    Run by
    City of Hope Medical Center

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.